Donato joins AmerisourceBergen executive team 

AmerisourceBergen has named Leslie Donato as EVP and chief strategy officer. She previously worked at Bayer and McKinsey & Co. Donato will report to Steve Collis, president and CEO. 

Provention Bio names Kell clinical development SVP

Provention Bio has appointed Dr. Sherron Kell as SVP of clinical development, leading the PRV-031 program. Kell will report to Dr. Eleanor Ramos, chief medical and operating officer. Kell was most recently VP at Impax Pharmaceuticals.

Millendo adds two executives 

Millendo Therapeutics has appointed Tamara Joseph as general counsel and corporate secretary and has promoted Ryan Zeidan as chief development officer. Joseph is succeeding Jeffrey Brinza, who said in March that he is retiring. Joseph most recently served as general counsel at Enzyvant Therapeutics. Zeidan was previously SVP of development at Millendo.

Axsome names Marek as commercial lead 

Axsome Therapeutics has picked David Marek as chief commercial officer, effective August 31. He previously worked at Amgen as VP and general manager of its neuroscience business unit. Marek has also worked at WebMD and Saatchi & Saatchi Healthcare Advertising.

Complexa names Danoff medical chief 

Complexa has appointed Theodore Danoff as chief medical officer. He was previously chief medical officer and SVP of clinical and medical affairs at Clarus Therapeutics. Danoff will lead strategy, direction and execution of Complexa’s clinical development programs. 

Curis hires two execs 

Curis has appointed Reinhard von Roemeling as SVP of clinical development and Christine Guertin as VP of regulatory affairs and quality assurance. Von Roemeling was previously global head of research and development at Huya Bioscience International. Guertin was most recently head of regulatory affairs at Synlogic. 

Client-side people moves courtesy of MM&M sister brand The PMD.

The Escalator is a weekly roundup of notable people moves in the pharmaceutical and healthcare marketing industries. For submissions, email Frank Washkuch at